Elazizi Lamiaa, Essafi Mohammed Amine, Hanane Aabi, Aynaou Hayat, Salhi Houda, El Ouahabi Hanan
Department of Endocrinology, Diabetology, Metabolic Diseases and Nutrition, Hassan II University Hospital Center, Fez, MAR.
Cureus. 2022 Aug 4;14(8):e27687. doi: 10.7759/cureus.27687. eCollection 2022 Aug.
Background and objective Gynecomastia is defined as a benign proliferation of male breast glandular tissue, either unilateral or bilateral, resulting from an imbalance of testosterone and estrogen. In this study, we aimed to describe the clinical, etiological, and therapeutic aspects of gynecomastia. Materials and methods A retrospective, descriptive study was conducted in the Department of Endocrinology, Diabetology, and Nutrition at the Hassan II University Hospital in Fez, Morocco, over a period of 10 years. We included all patients admitted for exploration and treatment of gynecomastia. The data were analyzed using Microsoft Excel 2016 and SPSS Statistics version 18 (IBM, Armonk, NY). Results A total of 86 patients were included in this study; the mean age of the patients was 33 years (range: 15-86 years). A family history of gynecomastia was found in 4.6%. Isolated gynecomastia was the most frequent symptom (60.4% of cases). It was bilateral in 54% of cases, stage II in 63% of patients, stage I in 17%, and stage III in 20%. The first-line assessment (renal insufficiency, hepatic insufficiency/cirrhosis, dysthyroidism)was normal in the majority of cases. The etiologies were dominated by hypogonadism in 32.6% of cases, pubertal gynecomastia in 21%, and senile gynecomastia in 8.1%. Regarding treatment, 42% of patients received an etiological treatment, while surgical treatment was provided in 28% of cases, observation in 15% of cases, and androgen therapy in 15%. Pathological examination of all surgical specimens was benign. The follow-up was marked by 30.3% of static gynecomastia, 29% of regression, 17.5% of good response after surgery, and 24.4% of treatment refusal. Conclusions It is important to adopt a step-by-step approach in treating gynecomastia, starting with detailed questioning and clinical examination. The surgical treatment is currently the treatment of choice, the final goal of which is good aesthetic as well as psychological outcomes.
背景与目的 男性乳房肥大症定义为男性乳腺腺体组织的良性增生,可为单侧或双侧,由睾酮和雌激素失衡所致。在本研究中,我们旨在描述男性乳房肥大症的临床、病因及治疗方面。材料与方法 在摩洛哥非斯哈桑二世大学医院内分泌、糖尿病与营养科进行了一项为期10年的回顾性描述性研究。我们纳入了所有因男性乳房肥大症探查及治疗而入院的患者。数据使用Microsoft Excel 2016和SPSS Statistics 18版(IBM,纽约州阿蒙克)进行分析。结果 本研究共纳入86例患者;患者平均年龄为33岁(范围:15 - 86岁)。4.6%的患者有男性乳房肥大症家族史。孤立性男性乳房肥大症是最常见症状(60.4%的病例)。54%的病例为双侧,63%的患者为II期,17%为I期,20%为III期。大多数病例的一线评估(肾功能不全、肝功能不全/肝硬化、甲状腺功能减退)正常。病因以性腺功能减退为主,占32.6%的病例,青春期男性乳房肥大症占21%,老年男性乳房肥大症占8.1%。关于治疗,42%的患者接受了病因治疗,28%的病例接受了手术治疗,15%的病例进行观察,15%的病例接受雄激素治疗。所有手术标本的病理检查均为良性。随访结果显示,30.3%为静止性男性乳房肥大症,29%有所消退,17.5%术后反应良好,24.4%拒绝治疗。结论 治疗男性乳房肥大症采用循序渐进的方法很重要,首先要进行详细询问和临床检查。目前手术治疗是首选治疗方法,其最终目标是获得良好的美学及心理效果。